in our free newsletter.

Thousands benefit from our email every week.

Trulieve Cannabis (TCNNF)

Trulieve dispensary in Tallahassee, Florida, Sept. 1, 2020.
Trulieve

California might be Bieber’s favorite weed spot, but investors should put Florida on the map, too.

Case in point: Trulieve Cannabis entered Florida by winning the first medical marijuana application in the state in 2015. Today, the company has 90 stores, over 600,000 patients and around 2 million square feet of cultivation in the Sunshine State, making it the top player in Florida’s cannabis market, with an estimated share of 46%.

Trulieve’s financials have grown tremendously, and even COVID-19 couldn’t stop the momentum. In 2020, revenue rose 106% from the 2019 level to US$521.5 million.

In the first six months of 2021, revenue surged another 89% year over year to US$408.9 million. The stock has nearly tripled since the beginning of 2020. But cooled in recent months.

In fact, Trulieve's pulled back more than 40% from its March peak. But given the growth momentum in its business, now could be a good time to add some Trulieve shares to your portfolio using an app that doesn't charge fees or commissions.

Green Thumb Industries (GTBIF)

STUTTGART, GERMANY - Aug 14, 2021: Mobile phone with webpage of American cannabis company Green Thumb Industries Inc  on screen in front of logo  Focus on top-left of phone display
Wirestock Creators / Shutterstock

Green Thumb is a vertically integrated cannabis company headquartered in Chicago. It has 16 manufacturing facilities, six consumer product brands, more than 60 operating stores and licenses for 111 retail locations.

Just like Trulieve, Green Thumb delivered huge returns to early investors, but the stock hasn’t been able to continue its upward momentum: Though it has gained 91% year over year, it's fallen about 4% over the last six months.

Business, however, is going up. Revenue totaled US$221.9 million for the quarter that ended in June, up 85.4% year over year. But the best part has been the bottom line. Green Thumb turned a profit of US$22.1 million for the quarter, compared to a loss of US$12.9 million in the year-ago period.

Curaleaf Holdings (CURLF)

Curaleaf dispensary in Daytona Beach, Florida.
Curaleaf

With a market cap of around US$8 billion, Curaleaf is a bigger company than both Trulieve and Green Thumb.

It has a huge presence in the U.S. cannabis industry, with 30 processing facilities, approximately 2 million square feet of cultivation capacity, 111 retail locations and around 2,000 wholesale partner accounts. Operational in 23 states, Curaleaf has exposure to a population of 192 million people.

During the second quarter, revenue increased 166% year over year to US$312 million. For the full year, the company is projected to bring in US$1.2 billion to US$1.3 billion.

With a revenue run rate trending at about US$100 million a month, Curaleaf is a name pot investors should not ignore.

Big risk, big returns?

Cannabis Stocks Exploding High Quality
ShutterstockProfessional / Shutterstock

Trulieve, Green Thumb and Curaleaf are listed in Canada and like even the best-known players in the pot sector can experience massive swings in their share prices — in either direction.

Cannabis is a nascent industry, so pot stocks have the potential to turn small amounts of money into something substantial. But don’t risk more than what you can afford to lose.

Even if you only have a modest investing budget, you may want to use an investing app that allows you to buy “slices” of shares of big-name stocks.

Going with a robo-advisor like Wealthsimple can also be a stress-free way to start investing.

And, those looking to take control of their investments should certainly explore online trading platforms. The best sites offer resources and tools to help investors make informed decisions as they build and manage their investment portfolios.

What to Read Next

Disclaimer

The content provided on Moneywise is information to help users become financially literate. It is neither tax nor legal advice, is not intended to be relied upon as a forecast, research or investment advice, and is not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. Tax, investment and all other decisions should be made, as appropriate, only with guidance from a qualified professional. We make no representation or warranty of any kind, either express or implied, with respect to the data provided, the timeliness thereof, the results to be obtained by the use thereof or any other matter.